A Uk Based Cost-Effectiveness Analysis Of Glycopyrronium Bromide A New Anti-Muscarinic Agent For The Maintenance Treatment Of Patients With COPD

被引：0
|
作者：
Malcolm, W. A. [1 ]
Keyzor, I. [1 ]
Radwan, A. [1 ]
Price, D. B. [2 ]
Asukai, Y. [3 ]
Ananthapavan, J. [3 ]
机构：
[1] Novartis Pharmaceut, Frimley, England
[2] Univ Aberdeen, Aberdeen, Scotland
[3] IMS Hlth, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2156
引用
收藏
页数：1
相关论文
共 50 条
  • [31] THE COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA™) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A UK ANALYSIS
    Bansback, N.
    Brennan, A.
    Sengupta, N.
    Pang, F.
    RHEUMATOLOGY, 2004, 43 : 77 - 77
  • [32] COST-EFFECTIVENESS ANALYSIS OF ALPHA-BLOCKER AND ANTI-MUSCARINIC COMBINATION TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS RELATED TO BENIGN PROSTATIC HYPERPLASIA AND OVERACTIVE BLADDER: APPLICATION TO THE UNITED KINGDOM
    Verheggen, B. G.
    Lee, R.
    Treur, M. J.
    Heeg, B.
    Botteman, M.
    Mollon, P.
    Trocio, J. N.
    Bavendam, T.
    Kaplan, S.
    VALUE IN HEALTH, 2009, 12 (03) : A199 - A199
  • [33] COST-EFFECTIVENESS ANALYSES OF UMECLIDINIUM BROMIDE 62.5 MCG VERSUS GLYCOPYRRONIUM 44 MCG AND UMECLIDINIUM BROMIDE 62.5 MCG VERSUS TIOTROPIUM 18 MCG IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UK
    Shah, D.
    Driessen, M.
    Risebrough, N.
    Baker, T. M.
    Naya, I
    Lloyd, E. J.
    Briggs, A.
    Ismaila, A.
    VALUE IN HEALTH, 2017, 20 (05) : A202 - A202
  • [34] Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/ vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China
    Zhou, Yuan
    Duan, Shujing
    Zhang, Lei
    Peng, Fangchen
    RESPIRATORY MEDICINE, 2024, 226
  • [35] A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure
    Thomas Ward
    Ruth D. Lewis
    Tray Brown
    Garth Baxter
    Antonio Ramirez de Arellano
    BMC Nephrology, 24
  • [36] A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure
    Ward, Thomas
    Lewis, Ruth D.
    Brown, Tray
    Baxter, Garth
    de Arellano, Antonio Ramirez
    BMC NEPHROLOGY, 2023, 24 (01)
  • [37] Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C infected patients in the UK
    Cure, Sandrine
    Guerra, Ines
    Dusheiko, Geoffrey M.
    HEPATOLOGY, 2014, 60 : 660A - 660A
  • [38] A COST-EFFECTIVENESS ANALYSIS OF DETOXIFICATION AND MAINTENANCE TREATMENT WITH BUPRENORPHINE/NALOXONE COMBINATION IN TURKEY
    Hren, R.
    VALUE IN HEALTH, 2016, 19 (07) : A525 - A525
  • [39] Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
    Christian Bührer
    Thomas Paling
    Richard Gale
    Tatiana Paulo
    Marloes Bagijn
    PharmacoEconomics - Open, 2024, 8 : 445 - 457
  • [40] Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
    Buhrer, Christian
    Paling, Thomas
    Gale, Richard
    Paulo, Tatiana
    Bagijn, Marloes
    PHARMACOECONOMICS-OPEN, 2024, 8 (03) : 445 - 457
12345